ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Solid Biosciences Inc. (SLDB) stock declined over -3.67%, trading at $5.78 on NASDAQ, down from the previous close of $6.00. The stock opened at $6.13, fluctuating between $5.50 and $6.15 in the recent session.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Employees | 88 |
Beta | 2.01 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Solid Biosciences Inc. (NASDAQ: SLDB) stock price is $5.78 in the last trading session. During the trading session, SLDB stock reached the peak price of $6.15 while $5.50 was the lowest point it dropped to. The percentage change in SLDB stock occurred in the recent session was -3.67% while the dollar amount for the price change in SLDB stock was -$0.22.
The NASDAQ listed SLDB is part of Biotechnology industry that operates in the broader Healthcare sector. Solid Biosciences Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Ilan Ganot
Co-founder, Strategic Advisor to the Chief Executive Officer & Director
Mr. Gilad David Hayeem
Co-Founder
Mr. Stephen J. Di Palma M.B.A, M.B.A.
Consultant
Mr. David Tyronne Howton Jr., J.D.
Chief Admin. Officer & Sec.
Ms. Erin Powers Brennan
Chief Legal Officer & Sec.
Mr. Paul Herzich
Chief Technology Officer
Dr. Carl Ashley Morris Ph.D.
Chief Scientific Officer of Neuromuscular
Mr. Ian F. Smith A.C.A., ACA, C.P.A., CPA
Executive Chair
Mr. Alexander G. Cumbo
Pres, Chief Executive Officer & Director
Mr. Matthew Bennett Arnold
Co-Founder & Board Member
Ms. Annie Ganot
Co-Founder & Head of Patient Advocacy
Dr. Andrey Juan Zarur Ph.D.
Co-Founder
Mr. Kevin Tan C.F.A.
Chief Financial Officer & Treasurer
SLDB's closing price is 108.33% higher than its 52-week low of $2.88 where as its distance from 52-week high of $15.05 is -60.13%.
Number of SLDB employees currently stands at 88.
Official Website of SLDB is: https://www.solidbio.com
SLDB could be contacted at phone 617 337 4680 and can also be accessed through its website. SLDB operates from 141 Portland Street, Cambridge, MA 02139, United States.
SLDB stock volume for the day was 2.14M shares. The average number of SLDB shares traded daily for last 3 months was 2.09M.
The market value of SLDB currently stands at $441.12M with its latest stock price at $5.78 and 76.32M of its shares outstanding.